In this GEN webinar, join Ebihara Takashi, PhD, COO of GeneFrontier, and Galit Meshulam-Simon, PhD, Associate Director, Commercial Applications at Elegen, as they present a case study demonstrating the exceptional properties and high-fidelity performance of ENFINIA Linear DNA as evaluated in GeneFrontier’s cell-free protein synthesis PUREfrex® system. These results showcase ENFINIA’s outperformance in terms of DNA purity, transcription efficiency, and robust protein expression for various constructs.

Attendees will learn:

• How this powerful combination eliminates the need for cloning or PCR amplification, significantly streamlining TXTL workflows
• How to reduce hands-on time and enable higher-throughput protein screening for synthetic biology, protein engineering, and drug discovery applications
• How to apply ENFINIA Linear DNA for challenging sequences such as long repeats, GC-rich promoters, and homopolymers